|
1
|
Cheung KS and Leung WK: Gastrointestinal
bleeding in patients on novel oral anticoagulants: Risk, prevention
and management. World J Gastroenterol. 23:1954–1963.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Desai J, Kolb JM, Weitz JI and Aisenberg
J: Gastrointestinal bleeding with the new oral anticoagulants -
defining the issues and the management strategies. Thromb Haemost.
110:205–212. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Holster IL, Valkhoff VE, Kuipers EJ and
Tjwa ET: New oral anticoagulants increase risk for gastrointestinal
bleeding: A systematic review and meta-analysis. Gastroenterology.
145:105–112.e15. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
He Y, Wong IC, Li X, Anand S, Leung WK,
Siu CW and Chan EW: The association between non-vitamin K
antagonist oral anticoagulants and gastrointestinal bleeding: A
meta-analysis of observational studies. Br J Clin Pharmacol.
8:285–300. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Malfertheiner P, Megraud F, O'Morain CA,
Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton
J, Graham DY, et al: European Helicobacter and Microbiota Study
Group and Consensus Panel. Management of Helicobacter pylori
infection - The Maastricht v/Florence Consensus Report. Gut.
66:6–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chan EW, Lau WC, Leung WK, Mok MT, He Y,
Tong TS and Wong IC: Prevention of dabigatran-related
gastrointestinal bleeding with gastroprotective agents: A
population-based study. Gastroenterology. 149:586–595.e3.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dans AL, Connolly SJ, Wallentin L, Yang S,
Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW,
Reilly PA and Yusuf S: Concomitant use of antiplatelet therapy with
dabigatran or warfarin in the randomized evaluation of long-term
anticoagulation therapy (RE-LY) trial. Circulation. 127:634–640.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Desai J, Granger CB, Weitz JI and
Aisenberg J: Novel oral anticoagulants in gastroenterology
practice. Gastrointest Endosc. 78:227–239. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Heidbuchel H, Verhamme P, Alings M, Antz
M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ and Kirchhof
P: Updated European Heart Rhythm Association Practical Guide on the
use of non-vitamin k antagonist anticoagulants in patients with
non-valvular atrial fibrillation. Europace. 17:1467–1507.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yu M, Zhang R, Ni P, Chen S and Duan G:
Helicobacter pylori infection and psoriasis: A systematic
review and meta-analysis. Medicina (Kaunas). 55(645)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Blech S, Ebner T, Ludwig-Schwellinger E,
Stangier J and Roth W: The metabolism and disposition of the oral
direct thrombin inhibitor, dabigatran, in humans. Drug Metab
Dispos. 36:386–399. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Eikelboom JW, Wallentin L, Connolly SJ,
Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S and
Hohnloser SH: Risk of bleeding with 2 doses of dabigatran compared
with warfarin in older and younger patients with atrial
fibrillation: An analysis of the randomized evaluation of long-term
anticoagulant therapy (RE-LY) trial. Circulation. 123:2363–2372.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Raghavan N, Frost CE, Yu Z, He K, Zhang H,
Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC and Zhang D:
Apixaban metabolism and pharmacokinetics after oral administration
to humans. Drug Metab Dispos. 37:74–81. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lip GY and Lane DA: Matching the NOAC to
the patient: Remember the modifiable bleeding risk factors. J Am
Coll Cardiol. 66:2282–2284. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pollack CV, Reilly PA, Eikelboom J, Glund
S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM,
Kamphuisen PW, et al: Idarucizumab for dabigatran reversal. N Engl
J Med. 373:511–520. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Connolly SJ, Milling TJ Jr, Eikelboom JW,
Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB,
Verhamme P, et al: Andexanet alfa for acute major bleeding
associated with factor Xa inhibitors. N Engl J Med. 375:1131–1141.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hong MJ, Lee SY, Kim JH, Sung IK, Park HS,
Shim CS and Jin CJ: Rebleeding after initial endoscopic hemostasis
in peptic ulcer disease. J Korean Med Sci. 29:1411–1415.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Baradarian R, Ramdhaney S, Chapalamadugu
R, Skoczylas L, Wang K, Rivilis S, Remus K, Mayer I, Iswara K and
Tenner S: Early intensive resuscitation of patients with upper
gastrointestinal bleeding decreases mortality. Am J Gastroenterol.
99:619–622. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Peloquin JM, Seraj SM, King LY, Campbell
EJ, Ananthakrishnan AN and Richter JM: Diagnostic and therapeutic
yield of endoscopy in patients with elevated INR and
gastrointestinal bleeding. Am J Med. 129:628–634. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ardeleanu V, Francu L and Georgescu C:
Neoangiogenesis. Assessment in esophageal adenocarcinomas. Indian J
Surg. 77 (Suppl 3):S971–S976. 2015.PubMed/NCBI View Article : Google Scholar
|
